J&J Skids After Dow Giant Beat Earnings Views, But ”Prudent” Guidance Disappoints

Jeff Jonas, portfolio manager at Gabelli Funds, called out depression drug Spravato. Spravato sales rose 44% year over year to $297 million and narrowly topped forecasts.

IN THE NEWS

© Gabelli Funds 2025

800-Gabelli
info@gabelli.com

Invest with Gabelli today